(Q40911128)

24 September 2017

1 reference

title

Therapeutic drug monitoring opportunities in cancer therapy (English)

1 reference

24 September 2017

McLeod HL

1

1 reference

24 September 2017

1 January 1997

1 reference

Pharmacology & Therapeutics

24 September 2017

1 reference

24 September 2017

74

1 reference

24 September 2017

39-54

1 reference

24 September 2017

1

1 reference

Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Population pharmacokinetics of carboplatin in children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

The clinical pharmacology of etoposide and teniposide

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Individual dose adaptation of anticancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

MTX clearance is more important for intermediate-risk ALL.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Methotrexate pharmacokinetics and prognosis in osteosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Etoposide dosage and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

A population model for the leukopenic effect of etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

The clinical pharmacology of 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Topoisomerase I and II activity in human breast, cervix, lung and colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Modeling interpatient pharmacodynamic variability of etoposide.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

DoseVersus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Influence of sex and age on fluorouracil clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Relationship between fluorouracil systemic exposure and tumor response and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Clinical pharmacodynamics of continuous-infusion etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Clinical relevance of biochemical modulation of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

24-hour plasma etoposide profile after oral and intravenous administration in children

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Association of intratumoral pharmacokinetics of fluorouracil with clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Pharmacodynamics in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Patient characteristics associated with high-risk methotrexate concentrations and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Altered protein binding of etoposide in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Relation of systemic exposure to unbound etoposide and hematologic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Clinical Pharmacokinetics of Carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Cancer statistics, 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2896%2900201-X

7 January 2021

10.1016/S0163-7258(96)00201-X

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9336015